A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.

A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.

PURPOSE: The primary aim of this study was to measure the objective tumor response rate following treatment with indisulam [E7070; N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide] as second-line therapy in patients with advanced non-small cell lung cancer. The secondary aims were to determine progr...

Full description

Bibliographic Details
Main Authors: Talbot, D, von Pawel, J, Cattell, E, Yule, S, Johnston, C, Zandvliet, A, Huitema, A, Norbury, C, Ellis, P, Bosquee, L, Reck, M
Format: Journal article
Language:English
Published: 2007

Similar Items

Similar Items